Program
Aripiprazole
Also written as “aripiprazole”, “Aripiprazole IM Depot” and “Antidepressant + Aripiprazole”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Tourette Syndrome · Autistic Disorder, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 1120 open or running | phase 4since Mar 26, 2004 | May 7, 2002 | none ahead |
| Johnson & Johnson | 40 open or running | phase 4since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Abdi İbrahim Otsuka | 10 open or running | phase 4since Feb 23, 2016 | Feb 23, 2016 | none ahead |
| Chengdu Kanghong Pharmaceutical Group | 10 open or running | no phasesince Jul 24, 2017 | Jul 24, 2017 | none ahead |
| cmg-pharmaceutical-co-ltd | 10 open or running | phase 1since Jun 4, 2015 | Jun 4, 2015 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | no phasesince Mar 23, 2026 | Mar 23, 2026 | Sep 5, 2027NCT07547384 |
| genovate-biotechnology-co-ltd | 10 open or running | phase 4since Oct 8, 2007 | Oct 8, 2007 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| H. Lundbeck | 10 open or running | phase 3since Oct 7, 2013 | Oct 7, 2013 | none ahead |
Also a collaborator on its studies: pra-health-sciences, covance and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Apr 2, 2009.
- May 2, 20172 phase 1 studies in SchizophreniaOtsuka · NCT03150771, NCT03287505
- May 11, 2017Phase 3 study in SchizophreniaOtsuka · NCT03172871 · 436 enrolled · China
- Jul 24, 2017Chengdu Kanghong Pharmaceutical Group's first study: no phase study in BioequivalenceNew to Chengdu Kanghong Pharmaceutical GroupChengdu Kanghong Pharmaceutical Group · NCT03232710 · 66 enrolled · China
- Sep 11, 2017Phase 1 study in SchizophreniaOtsuka · NCT03285503 · 12 enrolled · China
- Dec 13, 2017Phase 4 study in SchizophreniaOtsuka · NCT03376763 · 201 enrolled · Korea, Republic of
- Mar 27, 20182 phase 3 studiesOtsuka · NCT03487783, NCT03487770
- May 25, 2018Phase 4 study in SchizophreniaOtsuka · NCT03568500 · 44 enrolled · United Kingdom
- Sep 5, 2018Phase 4 study in Tourette SyndromeOtsuka · NCT03661983 · 36 enrolled · United States, Canada, Hungary
- Feb 12, 2019Phase 1 study in SchizophreniaOtsuka · NCT03854409 · 72 enrolled · United States
- Mar 21, 2019Phase 3 study in SchizophreniaOtsuka · NCT03892889 · 277 enrolled · United States
- Jul 19, 2019Phase 2 study in SchizophreniaOtsuka · NCT04030143 · 266 enrolled · United States
- Mar 27, 2023Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05804721 · 29 enrolled · Egypt
- Mar 29, 2024No phase study in Mental DisordersOtsuka · NCT06372210 · 54 enrolled · United States
- Mar 23, 2026CSPC Pharmaceutical Group's first study: no phase study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07547384 · 116 planned
Ahead
- Sep 5, 2027Primary completion: no phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07547384
TargetBeta
“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brexpiprazolerule | Otsuka | phase 4 | 70 |
Studies
The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07547384Schizophrenia | – | Not yet recruiting | CSPC Pharmaceutical Group | Sep 5, 2027 | 116 |
| NCT06372210Mental Disorders · United States | – | Completed | Otsuka | Jul 19, 2023 | 54 |
| NCT05804721Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Nov 7, 2022 | 29 |
| NCT04030143Schizophrenia · United States | 2 | Completed | Otsuka | Jul 8, 2020 | 266 |
| NCT03892889Schizophrenia · United States | 3 | Terminated | Otsuka | Aug 12, 2020 | 277 |
| NCT03854409Schizophrenia · United States | 1 | Completed | Otsuka | Apr 5, 2019 | 72 |
| NCT03661983Tourette Syndrome · United States, Canada, Hungary | 4 | Terminated | Otsuka | Jun 30, 2020 | 36 |
| NCT03568500Schizophrenia · United Kingdom | 4 | Completed | Otsuka | May 21, 2019 | 44 |
| NCT03487783Tourette Syndrome · China | 3 | Completed | Otsuka | Feb 14, 2020 | 121 |
| NCT03487770Autistic Disorder · China | 3 | Completed | Otsuka | Apr 21, 2020 | 111 |
| NCT03376763Schizophrenia · Korea, Republic of | 4 | Completed | Otsuka | Nov 19, 2021 | 201 |
| NCT03285503Schizophrenia · China | 1 | Completed | Otsuka | Oct 14, 2019 | 12 |
| NCT03232710Bioequivalence · China | – | UNKNOWN | Chengdu Kanghong Pharmaceutical Group | Apr 30, 2018 | 66 |
| NCT03287505Schizophrenia · China | 1 | Completed | Otsuka | Nov 8, 2019 | 24 |
| NCT03172871Schizophrenia · China | 3 | Completed | Otsuka | Jul 22, 2019 | 436 |
| NCT03150771Schizophrenia · United States | 1 | Completed | Otsuka | Apr 18, 2018 | 36 |
| NCT02722967Schizophrenia · United States | 2 | Completed | Otsuka | Sep 2016 | 49 |
| NCT02697045Schizophrenia · Turkey | 4 | Completed | Abdi İbrahim Otsuka | Mar 31, 2018 | 23 |
| NCT02634463Immunoassay · Belgium | 1 | Completed | Johnson & Johnson | Nov 9, 2016 | 81 |
| NCT02501109Schizophrenia | 1 | Completed | cmg-pharmaceutical-co-ltd | Feb 2016 | 36 |
| NCT02462473Schizophrenia · United States | 2 | Terminated | Johnson & Johnson | Jan 2016 | 9 |
| NCT02435836Schizophrenia | 3 | Terminated | Otsuka | Dec 2012 | 631 |
| NCT02220712Schizophrenia · Japan | 1 | Completed | Otsuka | Apr 2015 | 17 |
| NCT02091882Device Latency · United States | 4 | Completed | Otsuka | Apr 18, 2014 | 30 |
| NCT02054702Schizophrenia | 3 | Completed | Otsuka | Jun 2014 | 97 |
| NCT01981811Schizophrenia · United States | 2 | Withdrawn | Otsuka | May 2014 | 0 |
| NCT01959035Schizophrenia · United States | 3 | Completed | H. Lundbeck | Mar 2015 | 88 |
| NCT01942161Schizophrenia · Japan | 3 | Completed | Otsuka | Nov 2014 | 106 |
| NCT01942148Schizophrenia · Japan | 3 | Completed | Otsuka | Nov 2015 | 68 |
| NCT01909466Schizophrenia · United States | 1 | Completed | Otsuka | Mar 2014 | 141 |
| NCT01870999Schizophrenia · United States | 1 | Completed | Otsuka | Oct 2008 | 41 |
| NCT01727713Tourette Syndrome · United States, Canada, Hungary and more | 3 | Completed | Otsuka | Aug 2014 | 110 |
| NCT01727700Tourette Syndrome · United States, Canada, Germany and more | 3 | Completed | Otsuka | Aug 2013 | 133 |
| NCT01710709Bipolar I · United States, Canada, France and more | 3 | Completed | Otsuka | Nov 2016 | 748 |
| NCT01683058Schizophrenia · United States, Croatia, Latvia | 3 | Completed | Otsuka | Feb 2014 | 74 |
| NCT01663532Schizophrenia · United States, Croatia, Latvia | 3 | Completed | Otsuka | Aug 2013 | 340 |
| NCT01646827Schizophrenia · United States | 1 | Completed | Otsuka | Apr 2013 | 37 |
| NCT01617460Autistic Disorder · Japan | 3 | Completed | Otsuka | Oct 2016 | 86 |
| NCT01617447Autistic Disorder · Japan | 3 | Completed | Otsuka | Jun 2015 | 92 |
| NCT01607762Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 31 |
| NCT01552772Schizophrenia · United States | 1 | Completed | Otsuka | Apr 2012 | 60 |
| NCT01592201Schizophrenia · Korea, Republic of | 4 | Terminated | Johnson & Johnson | Jun 2013 | 13 |
| NCT01509053Schizophrenia · Belgium, Bulgaria, Canada | 3 | Terminated | Otsuka | Oct 2012 | 30 |
| NCT01432444Schizophrenia · United States, Canada | 3 | Completed | Otsuka | Dec 2013 | 493 |
| NCT01438060Alzheimer Disease | 3 | Completed | Otsuka | Jul 2010 | 232 |
| NCT01429831Depressive Disorder, Major · Taiwan | 4 | Completed | Otsuka | May 2013 | 300 |
| NCT01424449Depressive Disorder · United Kingdom | 1 | Completed | GlaxoSmithKline | Jul 2010 | 7 |
| NCT01418352Tourette Syndrome · United States, Bulgaria, Germany and more | 3 | Completed | Otsuka | Mar 12, 2014 | 83 |
| NCT01418339Tourette Syndrome · United States, Canada, Hungary and more | 3 | Completed | Otsuka | Nov 6, 2013 | 135 |
| NCT01416441Tourette Syndrome · United States, Bulgaria, Canada and more | 3 | Completed | Otsuka | Mar 13, 2014 | 170 |
| NCT01227668Irritability Associated With Autistic Disorder · United States | 4 | Completed | Otsuka | Jun 20, 2012 | 215 |
| NCT01149655Schizophrenia · United States, India, Malaysia and more | 3 | Completed | Otsuka | Nov 2013 | 252 |
| NCT01129882Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Otsuka | Dec 6, 2018 | 709 |
| NCT01123707Depressive Disorder, Major | 3 | Terminated | Otsuka | Sep 27, 2011 | 173 |
| NCT01122927Mania · United States, Bulgaria, Croatia and more | 3 | Terminated | Otsuka | Aug 2014 | 524 |
| NCT01111565Depressive Disorder, Major · United States, Canada, Croatia and more | 3 | Terminated | Otsuka | Sep 1, 2011 | 137 |
| NCT01111552Depressive Disorder, Major · United States, Australia, Bulgaria and more | 3 | Terminated | Otsuka | Sep 27, 2011 | 237 |
| NCT01111539Depressive Disorder, Major · United States, Estonia, Finland and more | 3 | Terminated | Otsuka | Sep 20, 2011 | 211 |
| NCT01001702Schizophrenia · Argentina, Croatia, India and more | 3 | Completed | Otsuka | Jul 2012 | 85 |
| NCT00882362Depressive Disorder, Major · Japan | 3 | Completed | Otsuka | Jul 2012 | 155 |
How it is read
Names in the registry
- “Aripiprazole”, 81 entries
- “aripiprazole”, 13 entries
- “Aripiprazole IM Depot”, 7 entries
- “Antidepressant + Aripiprazole”, 2 entries
- “Aripiprazole for Injection”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 15 studies
- Depressive Disorder, Major, 10 studies
- Tourette Syndrome, 8 studies
- Autistic Disorder, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.